Pasi Janne
机构: Dana Farber Cancer Institute
每年引用次数
引用次数
引用: 134,728
H-指数: 163
I10-指数 : 547
出版物: 1,257
Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer
Ken Takezawa , Isamu Okamoto , Kazuto Nishio , Pasi A. Jänne
Clinical Cancer Research 17 ( 8) 2140 -2148
107
2011
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
Mizuki Nishino , Nikhil H. Ramaiya , Emily S. Chambers , Anika E. Adeni
Journal for ImmunoTherapy of Cancer 4 ( 1) 84 -84
61
2016
Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies
Sai-Hong Ignatius Ou , Yutaka Fujiwara , Alice T. Shaw , Noboru Yamamoto
JTO Clinical and Research Reports 2 ( 1) 100108
2021
Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers
Hiu Wing Cheung , Jinyan Du , Jesse S. Boehm , Frank He
Cancer Discovery 1 ( 7) 608 -625
99
2011
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
Levi A. Garraway , Pasi A. Jänne
Cancer Discovery 2 ( 3) 214 -226
494
2012
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
Dalia Ercan , Chunxiao Xu , Masahiko Yanagita , Calixte S. Monast
Cancer Discovery 2 ( 10) 934 -947
202
2012
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR mutant Lung Cancer
Erin M. Tricker , Chunxiao Xu , Sharmeen Uddin , Marzia Capelletti
Cancer Discovery 5 ( 9) 960 -971
132
2015
Progress on Covalent Inhibition of KRASG12C
Kenneth D. Westover , Pasi A. Jänne , Nathanael S. Gray
Cancer Discovery 6 ( 3) 233 -234
15
2016
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Magda Bahcall , Taebo Sim , Cloud P. Paweletz , Jyoti D. Patel
Cancer Discovery 6 ( 12) 1334 -1341
76
2016
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
James E. Butrynski , David R. D'Adamo , Jason L. Hornick , Paola Dal Cin
The New England Journal of Medicine 363 ( 18) 1727 -1733
560
2010
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak , Yung-Jue Bang , D. Ross Camidge , Alice T. Shaw
The New England Journal of Medicine 363 ( 18) 1693 -1703
5,120
2010
Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
Gad Getz , David J. Kwiatkowski , Scott L. Carter , David M. Sabatini
The New England Journal of Medicine 371 ( 15) 1426 -1433
205
2014
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Pasi A. Jänne , James Chih-Hsin Yang , Dong-Wan Kim , David Planchard
The New England Journal of Medicine 372 ( 18) 1689 -1699
2,061
2015
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Susumu Kobayashi , Titus J. Boggon , Tajhal Dayaram , Pasi A. Jänne
The New England Journal of Medicine 352 ( 8) 786 -792
4,524
2005
Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations
Atsuko Ogino , Jihyun Choi , Mika Lin , Margaret K. Wilkens
Molecular Oncology 15 ( 1) 27 -42
3
2021
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.
Jaebong Jang , Jieun Son , Eunyoung Park , Takayuki Kosaka
Angewandte Chemie 57 ( 36) 11629 -11633
24
2018
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
Yanan Kuang , Andrew Rogers , Beow Y. Yeap , Lilin Wang
Clinical Cancer Research 15 ( 8) 2630 -2636
194
2009
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
Bruce E. Johnson , David M. Jackman , Vincent A. Miller , Leigh-Anne Cioffredi
Clinical Cancer Research 15 ( 16) 5267 -5273
487
2009
Integration of Molecular Profiling into the Lung Cancer Clinic
William Pao , Mark G. Kris , A. John Iafrate , Marc Ladanyi
Clinical Cancer Research 15 ( 17) 5317 -5322
72
2009
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Jeffrey A. Engelman , Pasi A. Jänne
Clinical Cancer Research 14 ( 10) 2895 -2899
762
2008